SLC5A2 and diabetic neuropathy: The short, 4-week study duration may not be sufficiently long to provide a reliable assessment of the long-term effects of SGLT-2 inhibitors on neuropathy, particularly given that diabetic neuropathy is typically a slowly progressive condition.